BioXcel Therapeutics raises $30.4M net, satisfies Oaktree financing covenant

BioXcel Therapeutics, Inc.

Raised $30.4M net from Nov 2024 ($6.2M), Mar 2025 ($13.0M), and ATM ($11.2M) financings, satisfying the Oaktree Financing Covenant.
Covenant required $29M net by Aug 15, 2025 or 30 days after SERENITY Phase 3 final readout; now satisfied.
As of Aug 8, 2025, BioXcel had 13,709,124 shares outstanding post-exercise of all pre-funded warrants.

item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.